Attached files

file filename
EX-31.2 - EX-31.2 - IASIS Healthcare LLCd389782dex312.htm
EX-31.1 - EX-31.1 - IASIS Healthcare LLCd389782dex311.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     .

COMMISSION FILE NUMBER: 333-117362

 

 

IASIS HEALTHCARE LLC

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   20-1150104

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

DOVER CENTRE

117 SEABOARD LANE, BUILDING E

FRANKLIN, TENNESSEE

  37067
(Address of principal executive offices)   (Zip Code)

(615) 844-2747

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  ☐    NO  ☒

(Note: As a voluntary filer not subject to the filing requirements of Sections 13 or 15(d) of the Exchange Act, the registrant has filed all reports pursuant to Section 13 or 15(d) of the Exchange Act during the preceding 12 months as if it were subject to such filing requirements.)

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    YES  ☒    NO  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  ☐    NO  ☒

As of May 12, 2017, 100% of the registrant’s common interests outstanding (all of which are privately owned and are not traded on any public market) were owned by IASIS Healthcare Corporation, its sole member.

 

 

 


Table of Contents

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION

     3  

Item 1. Financial Statements

     3  

Item  2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     36  

Item 3. Quantitative and Qualitative Disclosures about Market Risk

     56  

Item 4. Controls and Procedures

     56  

PART II. OTHER INFORMATION

     57  

Item 1. Legal Proceedings

     57  

Item 1A. Risk Factors

     57  

Item 6. Exhibits

     57  

Signatures

     58  

 

2


Table of Contents

PART I.

FINANCIAL INFORMATION

 

Item 1. Financial Statements

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In Thousands)

 

     March 31,     September 30,  
     2017     2016  
ASSETS     

Cash and cash equivalents

   $ 320,916     $ 345,685  

Accounts receivable, net

     368,613       342,368  

Inventories

     68,467       65,042  

Prepaid expenses and other current assets

     151,996       143,048  
  

 

 

   

 

 

 

Total current assets

     909,992       896,143  

Property and equipment, net

     938,121       939,784  

Goodwill

     777,344       767,659  

Other intangible assets, net

     14,916       16,601  

Other assets, net

     48,561       49,283  
  

 

 

   

 

 

 

Total assets

   $ 2,688,934     $ 2,669,470  
  

 

 

   

 

 

 
LIABILITIES AND EQUITY     

Accounts payable

   $ 142,056     $ 143,415  

Salaries and benefits payable

     54,561       47,464  

Accrued interest payable

     27,046       27,831  

Medical claims payable

     195,525       167,024  

Other accrued expenses and current liabilities

     129,784       138,996  

Current portion of long-term debt, capital leases and other long-term obligations, net

     17,556       18,086  
  

 

 

   

 

 

 

Total current liabilities

     566,528       542,816  

Long-term debt, capital leases and other long-term obligations, net

     1,823,468       1,830,840  

Deferred income taxes

     92,362       91,633  

Other long-term liabilities

     93,507       90,295  

Non-controlling interests with redemption rights

     120,777       120,809  

Member’s deficit

     (27,407     (23,247

Non-controlling interests

     19,699       16,324  
  

 

 

   

 

 

 

Total deficit

     (7,708     (6,923
  

 

 

   

 

 

 

Total liabilities and equity

   $ 2,688,934     $ 2,669,470  
  

 

 

   

 

 

 

See accompanying notes.

 

3


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In Thousands)

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2017     2016     2017     2016  

Revenues

        

Acute care revenue before provision for bad debts

   $ 600,080     $ 598,194     $ 1,202,257     $ 1,179,595  

Less: Provision for bad debts

     (95,825     (98,881     (198,813     (190,696
  

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     504,255       499,313       1,003,444       988,899  

Premium, service and other revenue

     338,791       321,974       679,483       635,236  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     843,046       821,287       1,682,927       1,624,135  

Costs and expenses

        

Salaries and benefits (includes stock-based compensation of $1,286, $1,737, $2,341 and $3,344, respectively)

     256,018       252,269       511,081       497,127  

Supplies

     86,850       84,113       176,379       168,964  

Medical claims

     275,335       268,030       551,389       534,737  

Rentals and leases

     22,234       21,968       44,036       43,300  

Other operating expenses

     141,835       148,137       279,340       277,887  

Medicare and Medicaid EHR incentives

     (34     (48     (805     (490

Interest expense, net

     31,915       34,033       61,660       66,643  

Depreciation and amortization

     26,100       27,057       52,497       53,250  

Management fees

     1,250       1,250       2,500       2,500  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     841,503       836,809       1,678,077       1,643,918  

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     1,543       (15,522     4,850       (19,783

Gain on disposal of assets, net

     628       237       933       725  
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     2,171       (15,285     5,783       (19,058

Income tax expense (benefit)

     897       (4,885     2,272       (5,377
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     1,274       (10,400     3,511       (13,681

Earnings (loss) from discontinued operations, net of income taxes

     (762     167       (848     (3,886
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     512       (10,233     2,663       (17,567

Net earnings attributable to non-controlling interests

     (3,725     (2,602     (7,626     (5,403
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to IASIS Healthcare LLC

   $ (3,213   $ (12,835   $ (4,963   $ (22,970
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes.

 

4


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

(In Thousands)

 

     Quarter Ended
March 31,
    Year Ended
March 31,
 
     2017     2016     2017     2016  

Net earnings (loss)

   $ 512     $ (10,233   $ 2,663     $ (17,567

Other comprehensive income

        

Change in fair value of highly effective interest rate hedges

     —         487       —         976  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income before income taxes

     —         487       —         976  

Change in income tax expense

     —         (178     —         (356
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income, net of income taxes

     —         309       —         620  
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     512       (9,924     2,663       (16,947

Net earnings attributable to non-controlling interests

     (3,725     (2,602     (7,626     (5,403
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss attributable to IASIS Healthcare LLC

   $ (3,213   $ (12,526   $ (4,963   $ (22,350
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes.

 

5


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED)

(In Thousands)

 

     Non-controlling
Interests with
Redemption Rights
    Member’s
Equity
    Non-controlling
Interests
     Total Equity  

Balance at September 30, 2016

   $ 120,809     $ (23,247   $ 16,324      $ (6,923

Net earnings (loss)

     4,728       (4,963     2,898        (2,065

Distributions to non-controlling interests

     (4,913     —         —          —    

Purchase of non-controlling interests

     (169     —         —          —    

Stock-based compensation

     —         2,341       —          2,341  

Other

     (1,458     242       477        719  

Adjustment to redemption value of non-controlling interests with redemption rights

     1,780       (1,780     —          (1,780
  

 

 

   

 

 

   

 

 

    

 

 

 

Balance at March 31, 2017

   $ 120,777     $ (27,407   $ 19,699      $ (7,708
  

 

 

   

 

 

   

 

 

    

 

 

 

See accompanying notes.

 

6


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In Thousands)

 

     Six Months Ended
March 31,
 
     2017     2016  

Cash flows from operating activities

    

Net earnings (loss)

   $ 2,663     $ (17,567

Adjustments to reconcile net earnings (loss) to net cash used in operating activities:

    

Depreciation and amortization

     52,497       53,250  

Amortization of loan costs

     3,869       4,012  

Amortization of deferred gain on sale-leaseback transaction

     (1,248     (1,248

Change in physician minimum revenue guarantees

     1,724       2,050  

Stock-based compensation

     2,341       3,344  

Deferred income taxes

     1,149       (8,512

Gain on disposal of assets, net

     (933     (725

Loss from discontinued operations, net

     848       3,886  

Changes in operating assets and liabilities, net of the effect of acquisitions and dispositions:

    

Accounts receivable, net

     (26,334     (24,684

Inventories, prepaid expenses and other current assets

     (13,254     30,091  

Accounts payable, other accrued expenses and other accrued liabilities

     27,776       34,155  
  

 

 

   

 

 

 

Net cash provided by operating activities — continuing operations

     51,098       78,052  

Net cash provided by (used in) operating activities — discontinued operations

     (855     637  
  

 

 

   

 

 

 

Net cash provided by operating activities

     50,243       78,689  
  

 

 

   

 

 

 

Cash flows from investing activities

    

Purchases of property and equipment

     (44,798     (62,050

Cash paid for acquisitions, net

     (14,318     (8,180

Proceeds from sale of assets

     68       166  

Change in other assets, net

     381       399  
  

 

 

   

 

 

 

Net cash used in investing activities

     (58,667     (69,665
  

 

 

   

 

 

 

Cash flows from financing activities

    

Payment of long-term debt, capital leases and other long-term obligations

     (11,268     (8,288

Payment of debt financing costs

     —         (5,179

Distributions to non-controlling interests

     (4,908     (5,563

Cash paid for the repurchase of non-controlling interests

     (169     (960
  

 

 

   

 

 

 

Net cash used in financing activities

     (16,345     (19,990
  

 

 

   

 

 

 

Change in cash and cash equivalents

     (24,769     (10,966

Cash and cash equivalents at beginning of period

     345,685       378,513  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 320,916     $ 367,547  
  

 

 

   

 

 

 

Supplemental disclosure of cash flow information:

    

Cash paid for interest

   $ 61,949     $ 60,258  
  

 

 

   

 

 

 

Cash received from income taxes, net

   $ (477   $ (11,411
  

 

 

   

 

 

 

Supplemental disclosure of non-cash information:

    

Financing obligation related to integrated clinical and revenue cycle systems conversion

     —       $ 23,409  
  

 

 

   

 

 

 

See accompanying notes.

 

7


Table of Contents

IASIS HEALTHCARE LLC

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. ORGANIZATION AND BASIS OF PRESENTATION

Organization

The unaudited condensed consolidated financial statements as of and for the quarters and six months ended March 31, 2017 and 2016, reflect the financial position, results of operations and cash flows of IASIS Healthcare LLC (“IASIS” or the “Company”). The Company’s sole member and parent company is IASIS Healthcare Corporation (“Holdings” or “IAS”).

IASIS provides high quality affordable healthcare services primarily in higher growth markets. At March 31, 2017, we owned or leased 17 acute care hospital facilities and one behavioral health hospital facility with a total of 3,600 licensed beds, several outpatient service facilities and 141 physician clinics.

IASIS’ continuing operations are in various regions including:

 

    Salt Lake City, Utah;

 

    Phoenix, Arizona;

 

    six cities in Texas, including Houston and San Antonio; and

 

    West Monroe, Louisiana.

The Company also owns and operates a managed care organization and insurer that manages healthcare services for more than 676,700 members through Health Choice Arizona, Inc. and related entities (“Health Choice” or the “Plan”), which includes multiple health plans, accountable care networks and managed care solutions. The Plan is headquartered in Phoenix, Arizona, with offices in Tampa, Florida and Salt Lake City, Utah.

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet of the Company at September 30, 2016, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and notes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2016.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all material adjustments (consisting of normal recurring items) necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year or any other future periods.

Principles of Consolidation

The unaudited condensed consolidated financial statements include the consolidated financial position and consolidated results of operations of the Company and its affiliates, which are controlled by the Company through the Company’s direct or indirect ownership of a majority interest and rights granted to the Company through certain variable interests. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying unaudited condensed consolidated financial statements and notes. Actual results could differ from those estimates.

General and Administrative

The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as “general and administrative” by the Company include the IASIS corporate office costs (excluding stock-based compensation costs), which were $21.5 million and $13.5 million for the quarters ended March 31, 2017 and 2016, respectively, and $39.0 million and $24.5 million for the six months ended March 31, 2017 and 2016, respectively.

 

8


Table of Contents

Cash and Cash Equivalents

The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains its cash and cash equivalent balances primarily with high credit quality financial institutions. The Company manages its credit exposure by placing its investments in U.S. Treasury securities or other high quality securities, and by periodically evaluating the relative credit standing of the financial institution.

Stock-Based Compensation

Although IASIS has no stock option plan, or outstanding stock options or other equity awards, the Company, through its parent, IAS, grants stock options for a fixed number of common shares and restricted stock units (“RSUs”) to its employees. The Company accounts for these stock-based incentive awards under the measurement and recognition provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation (“ASC 718”). Accordingly, the Company applies the fair value recognition provisions requiring all share-based payments to employees, including grants of employee stock options and RSUs, to be measured based on the grant-date fair value of the awards, with the resulting expense recognized in the income statement. In accordance with the provisions of ASC 718, the Company uses the Black-Scholes-Merton valuation model in determining the fair value of its share-based payments. Compensation cost for time-vested options and RSUs will generally be amortized on a straight-line basis over the requisite service periods of the awards, generally equal to the awards’ vesting periods, while compensation cost for options with market-based conditions are recognized on a graded schedule generally over the awards’ vesting periods.

Fair Value of Financial Instruments

The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), which provides a single definition of fair value, establishes a framework for measuring fair value, and expands disclosures concerning fair value measurements. The Company applies these provisions to the valuation and disclosure of certain financial instruments. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: (i) Level 1, which is defined as quoted prices in active markets that can be accessed at the measurement date; (ii) Level 2, which is defined as inputs other than quoted prices in active markets that are observable, either directly or indirectly; and (iii) Level 3, which is defined as unobservable inputs resulting from the existence of little or no market data, therefore potentially requiring an entity to develop its own assumptions.

Cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other current assets, accounts payable, salaries and benefits payable, accrued interest, medical claims payable, and other accrued expenses and current liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital leases and other long-term financing obligations also approximate their carrying value as they bear interest at current market rates.

The carrying value and fair value of the Company’s senior secured term loan facility and its 8.375% senior notes due 2019 (the “Senior Notes”) as of March 31, 2017 and September 30, 2016, were as follows (in thousands):

 

     Carrying Amount      Fair Value  
     March 31,
2017
     September 30,
2016
     March 31,
2017
     September 30,
2016
 

Senior secured term loan facility

   $ 963,469      $ 968,138      $ 967,280      $ 959,004  

Senior Notes

     848,300        847,916        832,902        771,284  

The estimated fair value of the Company’s senior secured term loan facility and its Senior Notes were based upon quoted market prices at that date and are categorized as Level 2 within the fair value hierarchy.

 

9


Table of Contents

Discontinued Operations

In accordance with the provisions of ASC 360, Property, Plant and Equipment (“ASC 360”), the Company has presented the operating results, financial position and cash flows of its previously disposed facilities as discontinued operations, net of income taxes, in the accompanying consolidated financial statements. Such reporting relates to disposals of components meeting the criteria for discontinued operations reporting prior to October 1, 2015, the effective date of Accounting Standards update (“ASU”) No. 2014-08, “Presentation of Financial Statements and Property, Plant and Equipment — Reporting Discontinued Operations and Disclosures of Components of an Entity”. ASU 2014-08 changed the criteria for reporting discontinued operations.

Recent Accounting Pronouncements

Newly Adopted

In February 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-02, “Consolidation”. ASU No. 2015-02 includes amendments that are intended to improve targeted areas of consolidation for legal entities including reducing the number of consolidation models from four to two and simplifying the FASB ASC. The provisions of ASU No. 2015-02 are effective for annual periods beginning after December 15, 2015. The amendments may be applied retrospectively in previously issued financial statements for one or more years with a cumulative effect adjustment to retained earnings as of the beginning of the first year restated. The Company’s adoption of ASU No. 2015-02 did not have an impact on its consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs”, which requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The guidance in the new standard is limited to the presentation of debt issuance costs. The recognition and measurement guidance for debt issuance costs are not affected by ASU No. 2015-03. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted ASU No. 2015-03 as of September 30, 2016, which resulted in the presentation of its debt issuance cost within long term debt.

Recently Issued

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. In addition, ASU No. 2014-09 will require new and enhanced disclosures. Companies can adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. ASU No. 2014-09 was originally scheduled to become effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early adoption was not permitted. In July 2015, the FASB decided that a deferral was necessary to provide companies adequate time to effectively implement the new standard. The FASB deferred the effective date by one year, but will permit entities to adopt one year earlier if they so choose. The Company is currently evaluating the effect of the new revenue recognition guidance and intends to adopt such guidance as of October 1, 2018.

In February 2016, the FASB issued ASU 2016-02, “Leases”, which requires lessees to recognize lease assets and lease liabilities on the balance sheet, including leases previously classified as operating. In addition, ASU 2016-02 implements changes to the lease classification criteria for lessors and eliminates portions of the previous real estate leasing guidance. ASU 2016-02 will become effective for fiscal years beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect of the new lease accounting guidance, and believes the primary effect of adopting the new standard will be to record assets and obligations for current operating leases. The Company intends to adopt such guidance as of October 1, 2019.

In March 2016, the FASB issued ASU 2016-09 “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which affects all entities that issue share-based payment awards to their employees. ASU 2016-09 simplifies the accounting for share-based payment transactions, including the income tax consequences and classification on the balance sheet and statement of cash flows. Portions of the guidance will only impact non-public entities. ASU 2016-09 will become effective for fiscal years beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the effect of the new share-based payment accounting guidance.

In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which clarifies the classification of certain cash receipts and cash payments on the statement of cash flows. ASU 2016-15 is effective retrospectively for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance may have on its consolidated cash flows.

 

10


Table of Contents

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other”, which simplifies the subsequent measurement of goodwill for public companies by eliminating step two from the goodwill impairment test. Under the new model, an entity should perform its test for impairment by comparing the fair value of a reporting unit with its carrying amount, and recognize any excess as an impairment charge. The provisions of ASU 2017-04 are effective for fiscal years beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the effect of the new guidance.

2. REVENUE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

Acute Care Revenue and Accounts Receivable

The Company’s healthcare facilities have entered into agreements with third-party payors, including government programs (Medicare, Medicaid and TRICARE), managed care health plans, including Medicare and Medicaid managed care health plans, commercial insurance companies and employers under which the facilities are paid based upon established charges, the cost of providing services, predetermined rates per diagnosis, fixed per diem rates or discounts from established charges. Additionally, the Company offers discounts through its uninsured discount program to all uninsured patients receiving healthcare services who do not qualify for assistance under state Medicaid, other federal or state assistance plans, or charity care.

In the ordinary course of business, the Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive. Because the Company does not pursue collection of amounts determined to qualify as charity care, they are not reported in acute care revenue. Accordingly, the Company records revenue deductions for patient accounts that meet its guidelines for charity care. The Company provides charity care to patients with income levels below 200% of the federal poverty level (“FPL”). Additionally, at all of the Company’s hospitals, a sliding scale of reduced rates is offered to uninsured patients who are not covered through federal, state or private insurance, with incomes between 200% and 400% of the FPL.

Acute care revenue is reported at the estimated net realizable amounts from third-party payors and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and are adjusted, if necessary, in future periods when final settlements are determined. The Company also records a provision for bad debts related to uninsured accounts, as well as co-insurance

and deductible balances due from insured patients, to reflect its self-pay accounts receivable at the estimated amounts expected to be collected. The sources of the Company’s hospital net patient revenue by payor before its provision for bad debts are summarized as follows:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2017     2016     2017     2016  

Medicare

     19.2     18.2     18.7     18.9

Managed Medicare

     12.4       10.3       11.8       10.4  

Medicaid and managed Medicaid

     9.8       11.9       9.8       12.4  

Managed care and other

     42.7       44.3       44.2       43.4  

Self-pay

     15.9       15.3       15.5       14.9  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

Allowance for Doubtful Accounts

The provision for bad debts and the associated allowance for doubtful accounts relate primarily to amounts due directly from patients. The Company does not pursue collection of amounts related to patients who qualify for charity care under the Company’s guidelines; therefore, charity care accounts are deducted from gross revenue and are not included in the provision for bad debts.

The Company’s estimation of its allowance for doubtful accounts is based primarily upon the type and age of the patient accounts receivable and the effectiveness of related collection efforts. The Company’s policy is to reserve a portion of all self-pay receivables, including amounts due from the uninsured and amounts related to co-payments and deductibles, as these charges are recorded. The Company monitors accounts receivable balances and the effectiveness of reserve policies on a regular basis and reviews various analytics to support the basis for its estimates. These efforts primarily consist of reviewing the following:

 

    Cash collections as a percentage of net patient revenue less bad debts;

 

    Changes in the aging and payor mix of accounts receivable, including increased focus on accounts due from the uninsured and accounts that represent co-payments and deductibles due from patients;

 

    Revenue and volume trends by payor, particularly the self-pay components;

 

11


Table of Contents
    Trending of days revenue in accounts receivable;

 

    Various allowance coverage statistics; and

 

    Historical write-off and collection experience using a hindsight or look-back approach.

At March 31, 2017 and September 30, 2016, the Company’s net self-pay receivables, including amounts due from uninsured patients and co-payment and deductible amounts due from insured patients, were $285.7 million and $279.1 million, respectively. At March 31, 2017 and September 30, 2016, the Company’s allowance for doubtful accounts was $229.8 million and $221.4 million, respectively.

Premium, Service and Other Revenue

Health Choice is the Company’s managed care organization and insurer that serves health plan enrollees in Arizona and Utah. The Plan derives most of its revenue through a contract in Arizona with the Arizona Health Care Cost Containment System (“AHCCCS”) to provide specified health services to qualified Medicaid enrollees through contracted providers. AHCCCS is the state agency that administers Arizona’s Medicaid program.

Effective October 1, 2013, Health Choice entered into a contract with AHCCCS with an initial term of three years, and two one-year renewal options at the discretion of AHCCCS. The contract is terminable without cause on 90 days’ written notice or for cause upon written notice if the Company fails to comply with any term or condition of the contract or fails to take corrective action as required to comply with the terms of the contract. Additionally, AHCCCS can terminate the contract in the event of the unavailability of state or federal funding.

Health Choice also provides coverage as a Medicare Advantage Prescription Drug (“MAPD”) Special Needs Plan (“SNP”) provider pursuant to a contract with the Centers for Medicare and Medicaid Services (“CMS”). The SNP allows Health Choice to offer Medicare and Part D drug benefit coverage for new and existing dual-eligible members (i.e. those that are eligible for Medicare and Medicaid). The contract with CMS includes successive one-year renewal options at the discretion of CMS and is terminable without cause on 90 days’ written notice or for cause upon written notice if the Company fails to comply with any term or condition of the contract or fails to take corrective action as required to comply with the terms of the contract.

In Arizona and surrounding states, the Plan subcontracts with hospitals, physicians and other medical providers to provide services to its Medicaid and Medicare enrollees in Apache, Coconino, Gila, Maricopa, Mohave, Navajo, Pima and Pinal counties, regardless of the actual costs incurred to provide these services.

Effective October 1, 2015, Health Choice’s joint venture, Health Choice Integrated Care LLC (“HCIC”) entered into a contract with AHCCCS to operate an integrated acute and behavioral health plan in Northern Arizona. The contract has an initial term of three years and includes two additional two-year renewal options that can be exercised at the discretion of AHCCCS. The contract is terminable by AHCCCS following HCIC’s failure to carry out a material contract term, condition or obligation. As of March 31, 2017, HCIC provided standalone behavioral health benefits to 228,600 plan members, which includes 62,300 Navajo Nation plan members that also receive health plan services through a state of Arizona Tribal Regional Behavioral Health Authority.

On January 1, 2017, Health Choice exited the Arizona marketplace exchange. The Company’s decision to exit the exchange was driven by the instability of the Health Reform marketplace, uncertainty and lack of funding around government premium stabilization programs, and the overall nature of the related regulatory environment.

Health Choice’s health plan contracts require the arrangement of healthcare services for enrolled patients in exchange for fixed monthly premiums, based upon negotiated per capita member rates. Capitation payments received by Health Choice are recognized as revenue in the month that members are entitled to healthcare services. Premium revenue includes adjustments to revenue related to the program settlement process for the Arizona managed Medicaid plan under the related state contract. This program settlement process reconciles estimated amounts due to or from the state based on the actual premium revenue and medical costs and contractually mandated limits on profits and losses. Although estimates of future program settlement amounts are recorded in current periods, the program settlement process typically occurs in the 18 months post-plan year, when actual (rather than projected) claims and member eligibility data become available and a net settlement amount is either due to or from the state. Adjustments to the estimates of future program settlement amounts are recorded as a component of premium revenue.

Health Choice is party to a contract with a large national insurer to provide management and administrative services to Medicaid enrollees in two separate geographic areas in the state of Florida. Under this contract, which covered 97,600 Medicaid enrollees as of March 31, 2017, Health Choice receives an administrative fee based upon the number of members served. The contract had an initial term of one year, with automatic annual renewal options that also provide each party with termination options.

 

12


Table of Contents

The sources of Health Choice’s premium, service and other revenue by major product line are summarized as follows:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2017     2016     2017     2016  

Medicaid and Exchange plans

     88.6     87.4     88.3     86.9

MAPD SNP

     9.9       9.7       9.4       9.8  

Service and other

     1.5       2.9       2.3       3.3  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

3. LONG-TERM DEBT, CAPITAL LEASES AND OTHER LONG-TERM OBLIGATIONS

Long-term debt, capital leases and other long-term obligations consist of the following (in thousands):

 

     March 31,
2017
     September 30,
2016
 

Senior secured term loan facility

   $ 963,469      $ 968,138  

Senior Notes

     848,300        847,916  

Capital leases and other long-term obligations

     37,493        43,685  

Deferred issuance costs

     (8,238      (10,813
  

 

 

    

 

 

 
     1,841,024        1,848,926  

Less current maturities

     17,556        18,086  
  

 

 

    

 

 

 
   $ 1,823,468      $ 1,830,840  
  

 

 

    

 

 

 

As of March 31, 2017 and September 30, 2016, the senior secured term loan facility balance reflects an original issue discount (“OID”) of $0.8 million and $1.2 million, respectively, which is net of accumulated amortization of $4.3 million and $3.9 million, respectively. The Senior Notes balance reflects an OID of $1.6 million and $1.9 million, respectively, which is net of accumulated amortization of $4.5 million and $4.2 million, respectively.

As of March 31, 2017 and September 30, 2016, reflecting the adoption of ASU No. 2015-03, deferred issuance costs associated with the senior secured term loans totaled $2.7 million and $3.9 million, respectively, and deferred issuance costs associated with the Senior Notes totaled $5.5 million and $6.9 million, respectively. These deferred issuance costs are amortized to interest expense over the term of their respective agreements.

As of March 31, 2017 and September 30, 2016, capital leases and other long-term obligations includes financing obligations totaling $19.9 million and $20.5 million, respectively, resulting from the Company’s sale-leaseback transactions. Additionally, as of March 31, 2017 and September 30, 2016, capital leases and other long-term obligations includes a financing obligation totaling $13.9 million and $16.2 million, respectively, related to the Company’s current conversion to a new integrated clinical and revenue cycle system.

 

13


Table of Contents

Senior Secured Credit Facilities

Amended Term Loan Facility

The Company is party to a senior credit agreement (the “Amended and Restated Credit Agreement”) with Wilmington Trust, National Association, as administrative agent, which provides for a $1.025 billion senior secured term loan facility maturing in May 2018 (the “Term Loan Facility”). Principal under the Term Loan Facility is due in equal quarterly installments in an aggregate annual amount equal to 1% of the principal amount of $1.007 billion outstanding as of the effective date, February 20, 2013, with the remaining balance due upon maturity of the Term Loan Facility.

Borrowings under the Term Loan Facility bear interest at a rate per annum equal to, at the Company’s option, either (1) a base rate determined by reference to the highest of (a) the federal funds rate plus 0.50%, (b) the prime rate (determined by reference to The Wall Street Journal) and (c) a one-month LIBOR rate, subject to a floor of 1.25%, plus 1.00%, in each case, plus a margin of 2.25% per annum or (2) the LIBOR rate for the interest period relevant to such borrowing, subject to a floor of 1.25%, plus a margin of 3.25% per annum.

The Term Loan Facility is unconditionally guaranteed by IAS and certain subsidiaries of the Company (collectively, the “Subsidiary Guarantors”; IAS and the Subsidiary Guarantors, the “Guarantors”) and is required to be guaranteed by all future material wholly-owned subsidiaries of the Company, subject to certain exceptions. All obligations under the Amended and Restated Credit Agreement are secured, subject to certain exceptions, by substantially all of the Company’s assets and the assets of the Guarantors, including (1) a pledge of 100% of the equity interests of the Company and the equity interests held by the Company and the Subsidiary Guarantors, subject to certain exceptions, (2) mortgage liens on all of the Company’s material real property and that of the Guarantors and (3) all proceeds of the foregoing.

The Amended and Restated Credit Agreement requires the Company to mandatorily prepay borrowings under the Term Loan Facility with net cash proceeds of certain asset dispositions, following certain casualty events, following certain borrowings or debt issuances and from a percentage of annual excess cash flow.

The Amended and Restated Credit Agreement contains certain restrictive covenants, including, among other things: (1) limitations on the incurrence of debt and liens; (2) limitations on investments other than, among other exceptions, certain acquisitions that meet certain conditions; (3) limitations on the sale of assets outside of the ordinary course of business; (4) limitations on dividends and distributions; and (5) limitations on transactions with affiliates, in each case, subject to certain exceptions. The Amended and Restated Credit Agreement also contains certain customary events of default, including, without limitation, a failure to make payments under the Term Loan Facility, cross-defaults, certain bankruptcy events and certain change of control events.

Term Loan Amendment

On May 4, 2017, the Company, Holdings, certain of their subsidiaries, the lenders party thereto, JPMorgan Chase Bank, N.A., as the Additional Term B-3 Lender (as defined therein), Wilmington Trust, National Association, as administrative agent, and the other agents named therein entered into an Amendment No. 4 to the Amended and Restated Credit Agreement (“Term Amendment No. 4”). Pursuant to Term Amendment No. 4, all of the then-outstanding term loans under the Amended and Restated Credit Agreement were refinanced with term loans (the “Term B-3 Loans”) maturing on February 17, 2021, subject to, if earlier, a springing maturity date of 91 days prior to the maturity date of the Senior Notes if any of the Senior Notes remains outstanding as of such date. The interest rate margins applicable to the Term B-3 Loans are 4.00%, for LIBOR-based loans, and 3.00%, for base rate loans, with a LIBOR floor of 1.25%. Term Amendment No. 4 also provides for a soft call prepayment premium applicable to certain repricing transactions involving the outstanding Term B-3 Loans. The soft call premium equals 1% of the amount of the Term B-3 Loans that are subject to certain repricing transactions occurring on or prior to May 4, 2018. Upon completion of Amendment No. 4, the outstanding term loan balance was $864.2 million, which reflected a $100.0 million pay down to certain holders.

In addition, certain of the baskets available to the Company under the negative covenants in its Amended and Restated Credit Agreement are suspended under the Amended and Restated Credit Agreement until such time, if any, as the Company has consummated a qualifying underwritten public offering and achieved a specified total gross leverage ratio.

Revolving Credit Facility

The Company is party to a revolving credit agreement (the “Revolving Credit Agreement”) with JPMorgan Chase Bank, N.A. (“JPMorgan”), as administrative agent, which provides for a $207.4 million senior secured revolving credit facility, of which up to $125.0 million may be utilized for the issuance of letters of credit (the “Revolving Credit Facility”). The Revolving Credit Facility matures in February 2021 (the “Stated Revolver Maturity Date”), provided that, if prior to the Stated Revolver Maturity Date, (x) any loans are outstanding under the Term Loan Facility on the date that is 91 days prior to the maturity date under the Term Loan Facility (such date, the “Springing Term Maturity Date”) or (y) any notes are outstanding under the Company’s indenture, dated as of May 3, 2011, by and among IASIS, IAS and The Bank of New York Mellon Trust Company, N.A., as Trustee, relating to the Company’s 8.375% Senior Notes due 2019 (the “Indenture”), on the date that is 91 days prior to the maturity date under the Indenture (such date, the “Springing Notes Maturity Date”), then the maturity date will automatically become the earlier of the Springing Term Maturity Date or the Springing Notes Maturity Date.

 

14


Table of Contents

The Revolving Credit Agreement provides the Company with the right to request additional commitments under the Revolving Credit Facility without the consent of the lenders thereunder, subject to a cap on aggregate commitments of $300.0 million, a pro forma senior secured net leverage ratio (as defined in the Revolving Credit Agreement) of less than or equal to 3.75 to 1.00 and customary conditions precedent.

The Revolving Credit Facility does not require installment payments prior to maturity.

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to, at the Company’s option, either (1) a base rate determined by reference to the highest of (a) the prime rate of JPMorgan, (2) the federal funds rate plus 0.50% and (3) a LIBOR rate subject to certain adjustments plus 1.00%, in each case, plus a margin of 2.50% per annum or (2) the LIBOR rate for the interest period relevant to such borrowing, plus a margin of 3.50% per annum. In addition to paying interest on outstanding principal under the Revolving Credit Facility, the Company is required to pay a commitment fee on the unutilized commitments under the Revolving Credit Facility, as well as pay customary letter of credit fees and agency fees.

The Revolving Credit Facility is unconditionally guaranteed by the Guarantors and is required to be guaranteed by all future material wholly-owned subsidiaries of the Company, subject to certain exceptions. All obligations under the Revolving Credit Agreement are secured, subject to certain exceptions, by substantially all of the Company’s assets and the assets of the Guarantors, including (1) a pledge of 100% of the equity interests of the Company and the equity interests held by the Company and the Subsidiary Guarantors, subject to certain exceptions, (2) mortgage liens on all of the Company’s material real property and that of the Guarantors and (3) all proceeds of the foregoing.

The Revolving Credit Agreement contains restrictive covenants and events of default substantially similar to the restrictive covenants and events of default in the Amended and Restated Credit Agreement; provided, that under the Revolving Credit Agreement, the Company is required to maintain, on a quarterly basis, a maximum senior secured gross leverage ratio (as defined in the Revolving Credit Agreement). In addition, certain of the baskets available to the Company under the negative covenants in the Amended and Restated Credit Agreement are suspended under the Revolving Credit Agreement until such time, if any, as the Company has consummated a qualifying underwritten public offering and achieved a specified total gross leverage ratio (as defined in the Revolving Credit Agreement).

Revolving Credit Agreement Amendment

On May 4, 2017, the Company, Holdings, the lenders party to the Revolving Credit Agreement as of such date and the Revolver Agent entered into an amendment to the Revolving Credit Agreement (“Revolver Amendment No. 1”). Pursuant to Revolver Amendment No. 1, the Revolving Credit Facility matures in February 2021 (the “Stated Revolver Maturity Date”), provided that, if prior to the Stated Revolver Maturity Date, (x) any loans are outstanding under the Term Loan Facility on the date that is 91 days prior to the maturity date of at least $100 million of loans under the Term Loan Facility (such date, the “Springing Term Maturity Date”) or (y) any notes are outstanding under the Indenture on the date that is 91 days prior to the maturity date under the Indenture (such date, the “Springing Notes Maturity Date”), then the maturity date will automatically become the earlier of the Springing Term Maturity Date or the Springing Notes Maturity Date.

8.375% Senior Notes due 2019

The Company, together with its wholly owned subsidiary IASIS Capital Corporation (together, the “Issuers”), issued $850.0 million aggregate principal amount of Senior Notes, which mature on May 15, 2019, pursuant to the Indenture. The Indenture provides that the Senior Notes are general unsecured, senior obligations of the Issuers, and initially will be unconditionally guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries.

At March 31, 2017, the outstanding principal balance of the Senior Notes was $849.9 million. The Senior Notes bear interest at a rate of 8.375% per annum, payable semi-annually, in cash in arrears, on May 15 and November 15 of each year.

The Issuers may redeem the Senior Notes, in whole or in part, at any time, at a price equal to 102.094% of the aggregate principal amount of the Senior Notes plus accrued and unpaid interest and special interest, if any, to but excluding the redemption date. Each subsequent year the redemption price declines 2.094 percentage points until 2017, at which point and thereafter the redemption price is equal to 100% of the aggregate principal amount of the Senior Notes plus accrued and unpaid interest and special interest, if any, to but excluding the redemption date.

The Indenture contains covenants that limit the Company’s (and its restricted subsidiaries’) ability to, among other things: (1) incur additional indebtedness or liens or issue disqualified stock or preferred stock; (2) pay dividends or make other distributions on, redeem or repurchase the Company’s capital stock; (3) sell certain assets; (4) make certain loans and investments; (5) enter into certain transactions with affiliates; (6) impose restrictions on the ability of a subsidiary to pay dividends or make payments or distributions to the Company and its restricted subsidiaries; and (7) consolidate, merge or sell all or substantially all of the Company’s assets. These covenants are subject to a number of important limitations and exceptions.

The Indenture also provides for events of default, which, if any of them occurs, may permit or, in certain circumstances, require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding Senior Notes to be due and payable immediately. If the Company experiences certain kinds of changes of control, it must offer to purchase the Senior Notes at 101% of their principal amount, plus accrued and unpaid interest and special interest, if any, to but excluding the repurchase date. Under certain circumstances, the Company will have the ability to make certain payments to facilitate a change of control transaction and to provide for the assumption of the Senior Notes by a new parent company resulting from such change of control transaction. If such change of control transaction is facilitated, the Issuers will be released from all obligations under the Indenture and the Issuers and the trustee will execute a supplemental indenture effectuating such assumption and release.

 

15


Table of Contents

4. GOODWILL

The following table presents the changes, if any, in the carrying amount of goodwill (in thousands):

 

     Acute
Care
     Health
Choice
     Total  

Balance at September 30, 2016

   $ 761,731      $ 5,928      $ 767,659  

Acquisition of imaging center

     9,099        —          9,099  

Adjustments related to acquisitions

     586        —          586  
  

 

 

    

 

 

    

 

 

 

Balance at March 31, 2017

   $ 771,416      $ 5,928      $ 777,344  
  

 

 

    

 

 

    

 

 

 

 

16


Table of Contents

5. INCOME TAXES

For the quarter ended March 31, 2017, the Company recorded an income tax expense of $0.9 million, resulting in an effective tax rate of 41.3%, compared to income tax benefit of $4.9 million, for an effective tax rate of (32.0%) in the prior year quarter. For the six months ended March 31, 2017, the Company recorded an income tax expense of $2.3 million, for an effective tax rate of 39.3%, compared to income tax benefit of $5.4 million, for an effective tax rate of (28.2%) in the prior year period. The change in the effective tax rate was primarily attributable to (1) a decrease in the nondeductible health insurer fee, and (2) an increase in the valuation allowance against deferred tax assets, and (3) an increase in net earnings from continuing operations, which altered the rate impact of nondeductible expenses, noncontrolling interests, and state income taxes including the Texas Margins tax.

6. COMMITMENTS AND CONTINGENCIES

Acute Care Revenue

The calculation of appropriate payments from the Medicare and Medicaid programs, including supplemental Medicaid reimbursement, as well as terms governing agreements with other third-party payors are complex and subject to interpretation. Final determination of amounts earned under the Medicare and Medicaid programs often occurs subsequent to the year in which services are rendered because of audits by the programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for adjustments that may result from such routine audits and appeals.

Professional, General and Workers’ Compensation Liability Risks

The Company is subject to claims and legal actions incidental to the Company’s business, including claims relating to patient treatment and personal injuries. To cover these types of claims and actions, the Company maintains professional and general liability insurance in excess of self-insured retentions through a commercial insurance carrier in amounts that the Company believes to be sufficient for its operations, although, potentially, some claims may exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is currently not a party to any proceedings that, in the Company’s opinion, would have a material adverse effect on the Company’s business, financial condition or results of operations. The Company expenses an estimate of the costs it expects to incur under the self-insured retention exposure for professional and general liability claims using historical claims data, demographic factors, severity factors, current incident logs and other actuarial analysis. At March 31, 2017 and September 30, 2016, the Company’s professional and general liability accrual for asserted and unasserted claims totaled $59.5 million and $54.2 million, respectively, with the current portion totaling $17.4 million at both periods.

The Company is subject to claims and legal actions in the ordinary course of business relative to workers’ compensation matters. To cover these types of claims, the Company maintains workers’ compensation insurance coverage with a self-insured retention. The Company accrues the costs of workers’ compensation claims based upon estimates derived from its claims experience.

Health Choice

Health Choice has entered into capitated contracts whereby the Plan provides healthcare services in exchange for fixed periodic and supplemental payments from AHCCCS, ADHS and CMS. These services are provided regardless of the actual costs incurred to provide these services. The Plan receives reinsurance and other supplemental payments from AHCCCS to cover certain costs of healthcare services that exceed certain thresholds. The Company believes the capitated payments, together with reinsurance and other supplemental payments are sufficient to pay for the services Health Choice is obligated to deliver. As of March 31, 2017, the Company has provided performance guaranties in the form of a letter of credit totaling $72.0 million for the benefit of AHCCCS, a surety bond for the benefit of ADHS totaling $21.3 million and a demand note totaling $12.0 million for the benefit of CMS to support its obligations under the Health Choice contracts to provide and pay for the related healthcare services. The amount of these performance guaranties are generally based in part upon the membership in the Plan and the related capitation revenue paid to Health Choice.

 

17


Table of Contents

Acquisitions

The Company has acquired and in the future may choose to acquire businesses with prior operating histories. Such businesses may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, such as billing and reimbursement, fraud and abuse and similar anti-referral laws. Although the Company has procedures designed to conform business practices to its policies following the completion of any acquisition, there can be no assurance that the Company will not become liable for previous activities of prior owners that may later be asserted to be improper by private plaintiffs or government agencies. Although the Company generally seeks to obtain indemnification from prospective sellers covering such matters, there can be no assurance that any such matter will be covered by indemnification, or if covered, that such indemnification will be adequate to cover potential losses and fines.

Other

On January 14, 2016, CMS entered into a Systems Improvement Agreement (“SIA”) with St. Joseph Medical Center (“SJMC”) located in Houston, Texas. The SIA acted to stay the scheduled termination of SJMC’s Medicare Provider Agreement, which resulted from the hospital’s alleged failure to comply with certain Medicare program conditions of participation. As required by the terms of the SIA, the Company retained an independent consultant to assist it in developing and implementing a corrective action plan. The original term of the SIA was eighteen months. In April 2017, CMS and SJMC amended the SIA to extend it by three-and-a-half months. The SIA is now scheduled to expire sixty days after CMS provides SJMC with written findings following a full certification survey, which survey may occur sometime between July 1, 2017 and October 31, 2017.

 

18


Table of Contents

7. SEGMENT INFORMATION

The Company’s reportable operating segments consist of (1) acute care hospitals and related healthcare businesses, collectively and (2) Health Choice. The following is a financial summary by business segment for the periods indicated (in thousands):

 

     For the Quarter Ended March, 2017  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 600,080      $ —        $ —        $ 600,080  

Less: Provision for bad debts

     (95,825      —          —          (95,825
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     504,255        —          —          504,255  

Premium, service and other revenue

     —          338,791        —          338,791  

Revenue between segments

     4,976        —          (4,976      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     509,231        338,791        (4,976      843,046  

Salaries and benefits (excludes stock-based compensation)

     233,658        21,074        —          254,732  

Supplies

     86,760        90        —          86,850  

Medical claims

     —          280,311        (4,976      275,335  

Rentals and leases

     21,196        1,038        —          22,234  

Other operating expenses

     127,212        14,623        —          141,835  

Medicare and Medicaid EHR incentives

     (34      —          —          (34
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     40,439        21,655        —          62,094  

Interest expense, net

     31,915        —          —          31,915  

Depreciation and amortization

     24,766        1,334        —          26,100  

Stock-based compensation

     1,286        —          —          1,286  

Management fees

     1,250        —          —          1,250  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (18,778      20,321        —          1,543  

Gain on disposal of assets, net

     628        —          —          628  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before income taxes

   $ (18,150    $ 20,321      $ —        $ 2,171  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

19


Table of Contents
     For the Quarter Ended March 31, 2016  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 598,194      $ —        $ —        $ 598,194  

Less: Provision for bad debts

     (98,881      —          —          (98,881
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     499,313        —          —          499,313  

Premium, service and other revenue

     —          321,974        —          321,974  

Revenue between segments

     4,499        —          (4,499      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     503,812        321,974        (4,499      821,287  

Salaries and benefits (excludes stock-based compensation)

     232,018        18,514        —          250,532  

Supplies

     83,864        249        —          84,113  

Medical claims

     —          272,529        (4,499      268,030  

Rentals and leases

     20,995        973        —          21,968  

Other operating expenses

     130,623        17,514        —          148,137  

Medicare and Medicaid EHR incentives

     (48      —          —          (48
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     36,360        12,195        —          48,555  

Interest expense, net

     34,033        —          —          34,033  

Depreciation and amortization

     25,706        1,351        —          27,057  

Stock-based compensation

     1,737        —          —          1,737  

Management fees

     1,250        —          —          1,250  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (26,366      10,844        —          (15,522

Gain on disposal of assets, net

     237        —          —          237  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before income taxes

   $ (26,129    $ 10,844      $ —        $ (15,285
  

 

 

    

 

 

    

 

 

    

 

 

 

 

20


Table of Contents
     For the Six Months Ended March 31, 2017  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 1,202,257      $ —        $ —        $ 1,202,257  

Less: Provision for bad debts

     (198,813      —          —          (198,813
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     1,003,444        —          —          1,003,444  

Premium, service and other revenue

     —          679,483        —          679,483  

Revenue between segments

     10,089        —          (10,089      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     1,013,533        679,483        (10,089      1,682,927  

Salaries and benefits (excludes stock-based compensation)

     466,253        42,487        —          508,740  

Supplies

     176,155        224        —          176,379  

Medical claims

     —          561,478        (10,089      551,389  

Rentals and leases

     41,989        2,047        —          44,036  

Other operating expenses

     245,432        33,908        —          279,340  

Medicare and Medicaid EHR incentives

     (805      —          —          (805
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     84,509        39,339        —          123,848  

Interest expense, net

     61,660        —          —          61,660  

Depreciation and amortization

     49,763        2,734        —          52,497  

Stock-based compensation

     2,341        —          —          2,341  

Management fees

     2,500        —          —          2,500  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

     (31,755      36,605        —          4,850  

Gain (loss) on disposal of assets, net

     933        —          —          933  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before income taxes

   $ (30,822    $ 36,605      $ —        $ 5,783  
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment assets

   $ 2,162,555      $ 526,379         $ 2,688,934  
  

 

 

    

 

 

       

 

 

 

Capital expenditures

   $ 43,753      $ 1,045         $ 44,798  
  

 

 

    

 

 

       

 

 

 

Goodwill

   $ 771,417      $ 5,927         $ 777,344  
  

 

 

    

 

 

       

 

 

 

 

21


Table of Contents
     For the Six Months Ended March 31, 2016  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 1,179,595      $ —        $ —        $ 1,179,595  

Less: Provision for bad debts

     (190,696      —          —          (190,696
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     988,899        —          —          988,899  

Premium, service and other revenue

     —          635,236        —          635,236  

Revenue between segments

     8,458        —          (8,458      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     997,357        635,236        (8,458      1,624,135  

Salaries and benefits (excludes stock-based compensation)

     458,366        35,417        —          493,783  

Supplies

     168,337        627        —          168,964  

Medical claims

     —          543,195        (8,458      534,737  

Rentals and leases

     41,369        1,931        —          43,300  

Other operating expenses

     242,802        35,085        —          277,887  

Medicare and Medicaid EHR incentives

     (490      —          —          (490
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     86,973        18,981        —          105,954  

Interest expense, net

     66,643        —          —          66,643  

Depreciation and amortization

     50,735        2,515        —          53,250  

Stock-based compensation

     3,344        —          —          3,344  

Management fees

     2,500        —          —          2,500  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (36,249      16,466        —          (19,783

Gain on disposal of assets, net

     725        —          —          725  
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before income taxes

   $ (35,524    $ 16,466      $ —        $ (19,058
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment assets

   $ 2,310,669      $ 461,342         $ 2,772,011  
  

 

 

    

 

 

       

 

 

 

Capital expenditures

   $ 61,585      $ 465         $ 62,050  
  

 

 

    

 

 

       

 

 

 

Goodwill

   $ 815,582      $ 5,757         $ 821,339  
  

 

 

    

 

 

       

 

 

 

 

(1) Adjusted EBITDA represents net earnings (loss) from continuing operations before net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation, gain (loss) on disposal of assets and management fees. Management fees represent monitoring and advisory fees paid to management companies affiliated with TPG and JLL. Management routinely calculates and communicates adjusted EBITDA and believes that it is useful to investors because it is commonly used as an analytical indicator within the healthcare industry to evaluate performance, allocate resources and measure leverage capacity and debt service ability. In addition, the Company uses adjusted EBITDA as a measure of performance for its business segments and for incentive compensation purposes. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to net earnings, cash flows generated by operating, investing, or financing activities or other financial statement data presented in the unaudited condensed consolidated financial statements as an indicator of financial performance or liquidity. Adjusted EBITDA, as presented, differs from “adjusted EBITDA” as defined under the Company’s Senior Secured Credit Facilities and may not be comparable to similarly titled measures of other companies.

 

22


Table of Contents

8. SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Senior Notes described in Note 3 are fully and unconditionally guaranteed on a joint and several basis by all of the Company’s existing 100% owned existing domestic subsidiaries, other than certain non-guarantor subsidiaries, which include Health Choice. In addition, the Senior Notes are not guaranteed by the Company’s non-wholly owned subsidiaries. The guarantees are subject to customary release provisions set forth in the Indenture for the Senior Notes.

Summarized condensed consolidating balance sheets at March 31, 2017 and September 30, 2016, condensed consolidating statements of operations for the quarters and six months ended March 31, 2017 and 2016, condensed consolidating statements of comprehensive income (loss) for the quarters and six months ended March 31, 2017 and 2016, and condensed consolidating statements of cash flows for the six months ended March 31, 2017 and 2016, for the Company, segregating the parent company issuer, the subsidiary guarantors, the subsidiary non-guarantors and eliminations, are found below.

 

23


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Balance Sheet

March 31, 2017 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations     Condensed
Consolidated
 
Assets            

Current assets

           

Cash and cash equivalents

   $ —       $ 231,127     $ 89,789      $ —       $ 320,916  

Accounts receivable, net

     —         56,970       311,643        —         368,613  

Inventories

     —         17,097       51,370        —         68,467  

Prepaid expenses and other current assets

     —         48,462       103,534        —         151,996  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total current assets

     —         353,656       556,336        —         909,992  

Property and equipment, net

     —         338,548       599,573        —         938,121  

Intercompany

     —         (205,736     205,736        —         —    

Net investment in and advances to subsidiaries

     1,886,039       —         —          (1,886,039     —    

Goodwill

     5,240       39,097       733,007        —         777,344  

Other intangible assets, net

     —         7,416       7,500        —         14,916  

Other assets, net

     4,253       31,831       12,477        —         48,561  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total assets

   $ 1,895,532     $ 564,812     $ 2,114,629      $ (1,886,039   $ 2,688,934  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
              —    

Liabilities and Equity

           

Current liabilities

           

Accounts payable

   $ —       $ 53,883     $ 88,173      $ —       $ 142,056  

Salaries and benefits payable

     —         24,739       29,822        —         54,561  

Accrued interest payable

     27,046       (3,218     3,218        —         27,046  

Medical claims payable

     —         —         195,525        —         195,525  

Other accrued expenses and current liabilities

     —         56,018       73,766        —         129,784  

Current portion of long-term debt, capital leases and other long-term obligations, net

     10,071       7,485       28,902        (28,902     17,556  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total current liabilities

     37,117       138,907       419,406        (28,902     566,528  

Long-term debt, capital leases and other long-term obligations, net

     1,793,460       30,008       592,269        (592,269     1,823,468  

Deferred income taxes

     92,362       —         —          —         92,362  

Other long-term liabilities

     —         92,506       1,001        —         93,507  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities

     1,922,939       261,421       1,012,676        (621,171     2,575,865  

Non-controlling interests with redemption rights

     —         120,777       —          —         120,777  

Equity

           

Member’s equity (deficit)

     (27,407     173,764       1,091,104        (1,264,868     (27,407

Non-controlling interests

     —         8,850       10,849        —         19,699  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total equity (deficit)

     (27,407     182,614       1,101,953        (1,264,868     (7,708
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities and equity

   $ 1,895,532     $ 564,812     $ 2,114,629      $ (1,886,039   $ 2,688,934  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

 

24


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Balance Sheet

September 30, 2016

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations     Condensed
Consolidated
 
Assets            

Current assets

           

Cash and cash equivalents

   $ —       $ 258,811     $ 86,874      $ —       $ 345,685  

Accounts receivable, net

     —         53,502       288,866        —         342,368  

Inventories

     —         15,268       49,774        —         65,042  

Prepaid expenses and other current assets

     —         33,286       109,762        —         143,048  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total current assets

     —         360,867       535,276        —         896,143  

Property and equipment, net

     —         323,373       616,411        —         939,784  

Intercompany

     —         (230,667     230,667        —         —    

Net investment in and advances to subsidiaries

     1,891,422       —         —          (1,891,422     —    

Goodwill

     5,240       32,072       730,347        —         767,659  

Other intangible assets, net

     —         7,601       9,000        —         16,601  

Other assets, net

     4,796       28,347       16,140        —         49,283  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total assets

   $ 1,901,458     $ 521,593     $ 2,137,841      $ (1,891,422   $ 2,669,470  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Liabilities and Equity

           

Current liabilities

           

Accounts payable

   $ —       $ 49,925     $ 93,490      $ —       $ 143,415  

Salaries and benefits payable

     —         19,738       27,726        —         47,464  

Accrued interest payable

     27,831       (3,220     3,220        —         27,831  

Medical claims payable

     —         —         167,024        —         167,024  

Other accrued expenses and current liabilities

     —         56,376       82,620        —         138,996  

Current portion of long-term debt, capital leases and other long-term obligations, net

     10,071       8,015       29,075        (29,075     18,086  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total current liabilities

     37,902       130,834       403,155        (29,075     542,816  

Long-term debt, capital leases and other long-term obligations, net

     1,795,170       35,670       611,424        (611,424     1,830,840  

Deferred income taxes

     91,633       —         —          —         91,633  

Other long-term liabilities

     —         89,285       1,010        —         90,295  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities

     1,924,705       255,789       1,015,589        (640,499     2,555,584  

Non-controlling interests with redemption rights

     —         120,809       —          —         120,809  

Equity

           

Member’s equity

     (23,247     136,613       1,114,310        (1,250,923     (23,247

Non-controlling interests

     —         8,382       7,942        —         16,324  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total equity

     (23,247     144,995       1,122,252        (1,250,923     (6,923
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities and equity

   $ 1,901,458     $ 521,593     $ 2,137,841      $ (1,891,422   $ 2,669,470  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

 

25


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Quarter Ended March 31, 2017 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Revenues

          

Acute care revenue before provision for bad debts

   $ —       $ 128,258     $ 476,798     $ (4,976   $ 600,080  

Less: Provision for bad debts

     —         (9,693     (86,132     —         (95,825
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —         118,565       390,666       (4,976     504,255  

Premium, service and other revenue

     —         —         338,791       —         338,791  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     —         118,565       729,457       (4,976     843,046  

Costs and expenses

          

Salaries and benefits

     1,286       83,274       171,458       —         256,018  

Supplies

     —         20,469       66,381       —         86,850  

Medical claims

     —         —         280,311       (4,976     275,335  

Rentals and leases

     —         5,729       16,505       —         22,234  

Other operating expenses

     —         37,329       104,506       —         141,835  

Medicare and Medicaid EHR incentives

     —         (55     21       —         (34

Interest expense, net

     31,915       —         12,598       (12,598     31,915  

Depreciation and amortization

     —         8,849       17,251       —         26,100  

Management fees

     1,250       (8,085     8,085       —         1,250  

Equity in earnings of affiliates

     (19,127     —         —         19,127       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     15,324       147,510       677,116       1,553       841,503  

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (15,324     (28,945     52,341       (6,529     1,543  

Gains on disposal of assets, net

     —         596       32       —         628  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (15,324     (28,349     52,373       (6,529     2,171  

Income tax expense

     897       —         —         —         897  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (16,221     (28,349     52,373       (6,529     1,274  

Gain (loss) from discontinued operations, net of income taxes

     410       (1,172     —         —         (762
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (15,811     (29,521     52,373       (6,529     512  

Net earnings attributable to non-controlling interests

     —         (2,165     (1,560     —         (3,725
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (15,811   $ (31,686   $ 50,813     $ (6,529   $ (3,213
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

26


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Quarter Ended March 31, 2016 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Revenues

          

Acute care revenue before provision for bad debts

   $ —       $ 135,637     $ 467,056     $ (4,499   $ 598,194  

Less: Provision for bad debts

     —         (10,971     (87,910     —         (98,881
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —         124,666       379,146       (4,499     499,313  

Premium, service and other revenue

     —         —         321,974       —         321,974  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     —         124,666       701,120       (4,499     821,287  

Costs and expenses

          

Salaries and benefits

     1,737       80,630       169,902       —         252,269  

Supplies

     —         20,856       63,257       —         84,113  

Medical claims

     —         —         272,529       (4,499     268,030  

Rentals and leases

     —         5,423       16,545       —         21,968  

Other operating expenses

     —         39,752       108,385       —         148,137  

Medicare and Medicaid EHR incentives

     —         (433     385       —         (48

Interest expense, net

     34,033       —         12,306       (12,306     34,033  

Depreciation and amortization

     —         9,820       17,237       —         27,057  

Management fees

     1,250       (7,736     7,736       —         1,250  

Equity in earnings of affiliates

     (7,097     —         —         7,097       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     29,923       148,312       668,282       (9,708     836,809  

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

     (29,923     (23,646     32,838       5,209       (15,522

Gain (loss) on disposal of assets, net

     —         (95     332       —         237  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (29,923     (23,741     33,170       5,209       (15,285

Income tax benefit

     (4,885     —         —         —         (4,885
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (25,038     (23,741     33,170       5,209       (10,400

Earnings (loss) from discontinued operations, net of income taxes

     (103     270       —         —         167  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (25,141     (23,471     33,170       5,209       (10,233

Net earnings attributable to non-controlling interests

     —         (2,602     —         —         (2,602
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (25,141   $ (26,073   $ 33,170     $ 5,209     $ (12,835
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

27


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Six Months Ended March 31, 2017 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Revenues

          

Acute care revenue before provision for bad debts

   $ —       $ 263,266     $ 949,080     $ (10,089   $ 1,202,257  

Less: Provision for bad debts

     —         (25,641     (173,172     —         (198,813
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —         237,625       775,908       (10,089     1,003,444  

Premium, service and other revenue

     —         —         679,483       —         679,483  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     —         237,625       1,455,391       (10,089     1,682,927  

Costs and expenses

          

Salaries and benefits

     2,341       166,926       341,814       —         511,081  

Supplies

     —         42,994       133,385       —         176,379  

Medical claims

     —         —         561,478       (10,089     551,389  

Rentals and leases

     —         10,921       33,115       —         44,036  

Other operating expenses

     —         66,587       212,753       —         279,340  

Medicare and Medicaid EHR incentives

     —         (55     (750     —         (805

Interest expense, net

     61,660       —         22,399       (22,399     61,660  

Depreciation and amortization

     —         17,927       34,570       —         52,497  

Management fees

     2,500       (16,242     16,242       —         2,500  

Equity in earnings of affiliates

     (40,954     —         —         40,954       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     25,547       289,058       1,355,006       8,466       1,678,077  

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (25,547     (51,433     100,385       (18,555     4,850  

Gain on disposal of assets, net

     —         899       34       —         933  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (25,547     (50,534     100,419       (18,555     5,783  

Income tax expense

     2,272       —         —         —         2,272  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (27,819     (50,534     100,419       (18,555     3,511  

Earnings (loss) from discontinued operations, net of income taxes

     457       (1,305     —         —         (848
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (27,362     (51,839     100,419       (18,555     2,663  

Net earnings attributable to non-controlling interests

     —         (4,718     (2,908     —         (7,626
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (27,362   $ (56,557   $ 97,511     $ (18,555   $ (4,963
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

28


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Six Months Ended March 31, 2016 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Revenue

          

Acute care revenue before provision for bad debts

   $ —       $ 266,208     $ 921,845     $ (8,458   $ 1,179,595  

Less: Provision for bad debts

     —         (25,689     (165,007     —         (190,696
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —         240,519       756,838       (8,458     988,899  

Premium, service and other revenue

     —         —         635,236       —         635,236  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     —         240,519       1,392,074       (8,458     1,624,135  

Costs and expenses

          

Salaries and benefits

     3,344       160,163       333,620       —         497,127  

Supplies

     —         41,712       127,252       —         168,964  

Medical claims

     —         —         543,195       (8,458     534,737  

Rentals and leases

     —         10,534       32,766       —         43,300  

Other operating expenses

     —         63,226       214,661       —         277,887  

Medicare and Medicaid EHR incentives

     —         (499     9       —         (490

Interest expense, net

     66,643       —         22,586       (22,586     66,643  

Depreciation and amortization

     —         19,348       33,902       —         53,250  

Management fees

     2,500       (15,698     15,698       —         2,500  

Equity in earnings of affiliates

     (17,672     —         —         17,672       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     54,815       278,786       1,323,689       (13,372     1,643,918  

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (54,815     (38,267     68,385       4,914       (19,783

Gain on disposal of assets, net

     —         358       367       —         725  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (54,815     (37,909     68,752       4,914       (19,058

Income tax expense (benefit)

     (7,163     —         1,786       —         (5,377
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (47,652     (37,909     66,966       4,914       (13,681

Earnings (loss) from discontinued operations, net of income taxes

     2,096       (5,982     —         —         (3,886
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (45,556     (43,891     66,966       4,914       (17,567

Net earnings attributable to non-controlling interests

     —         (5,403     —         —         (5,403
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (45,556   $ (49,294   $ 66,966     $ 4,914     $ (22,970
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

29


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Quarter Ended March 31, 2017 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Net earnings (loss)

   $ (15,811   $ (29,521   $ 52,373     $ (6,529   $ 512  

Other comprehensive income

          

Change in fair value of highly effective interest rate hedges

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income before income taxes

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Change in income tax expense

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income, net of income taxes

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (15,811     (29,521     52,373       (6,529     512  

Net earnings attributable to non-controlling interests

     —         (2,165     (1,560     —         (3,725
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (15,811   $ (31,686   $ 50,813     $ (6,529   $ (3,213
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

30


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Quarter Ended March 31, 2016 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations      Condensed
Consolidated
 

Net earnings (loss)

   $ (25,141   $ (23,471   $ 33,170      $ 5,209      $ (10,233

Other comprehensive income

            

Change in fair value of highly effective interest rate hedges

     487       —         —          —          487  
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive loss before income taxes

     487       —         —          —          487  

Change in income tax benefit

     (178     —         —          —          (178
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income, net of income taxes

     309       —         —          —          309  
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss)

     (24,832     (23,471     33,170        5,209        (9,924

Net earnings attributable to non-controlling interests

     —         (2,602     —          —          (2,602
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (24,832   $ (26,073   $ 33,170      $ 5,209      $ (12,526
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

 

31


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Six Months Ended March 31, 2017 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Net earnings (loss)

   $ (27,362   $ (51,839   $ 100,419     $ (18,555   $ 2,663  

Other comprehensive income

          

Change in fair value of highly effective interest rate hedges

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income before income taxes

     —         —         —         —         —    

Change in income tax benefit

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income, net of income taxes

     —         —         —         —         —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (27,362     (51,839     100,419       (18,555     2,663  

Net earnings attributable to non-controlling interests

     —         (4,718     (2,908     —         (7,626
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (27,362   $ (56,557   $ 97,511     $ (18,555   $ (4,963
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

32


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Six Months Ended March 31, 2016 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations      Condensed
Consolidated
 

Net earnings (loss)

   $ (45,556   $ (43,891   $ 66,966      $ 4,914      $ (17,567

Other comprehensive income

            

Change in fair value of highly effective interest rate hedges

     976       —         —          —          976  
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income before income taxes

     976       —         —          —          976  

Change in income tax benefit

     (356     —         —          —          (356
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income, net of income taxes

     620       —         —          —          620  
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss)

     (44,936     (43,891     66,966        4,914        (16,947

Net earnings attributable to non-controlling interests

     —         (5,403     —          —          (5,403
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (44,936   $ (49,294   $ 66,966      $ 4,914      $ (22,350
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

 

33


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended March 31, 2017 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Cash flows from operating activities

          

Net earnings (loss)

   $ (27,362   $ (51,839   $ 100,419     $ (18,555   $ 2,663  

Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:

          

Depreciation and amortization

     —         17,927       34,570       —         52,497  

Amortization of loan costs

     3,869       —         —         —         3,869  

Amortization of deferred gain on sale-leaseback transaction

     (1,248     —         —         —         (1,248

Change in physician minimum revenue guarantees

     —         73       1,651       —         1,724  

Stock-based compensation

     2,341       —         —         —         2,341  

Deferred income taxes

     1,149       —         —         —         1,149  

Loss on disposal of assets, net

     —         (831     (102     —         (933

Loss from discontinued operations, net

     (457     1,305       —         —         848  

Equity in earnings of affiliates

     (40,954     —         —         40,954       —    

Changes in operating assets and liabilities, net of the effect of acquisitions and dispositions:

          

Accounts receivable, net

     —         22,695       (49,029     —         (26,334

Inventories, prepaid expenses and other current assets

     —         (68,469     55,215       —         (13,254

Accounts payable, other accrued expenses and other accrued liabilities

     (785     32,614       (4,053     —         27,776  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities — continuing operations

     (63,447     (46,525     138,671       22,399       51,098  

Net cash used in operating activities — discontinued operations

     —         (855     —         —         (855
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     (63,447     (47,380     138,671       22,399       50,243  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from investing activities

          

Purchases of property and equipment

     —         (28,646     (16,152     —         (44,798

Cash paid for acquisitions, net

     —         (14,318     —         —         (14,318

Proceeds from sale of assets

     —         18       50       —         68  

Change in other assets, net

     —         (3,326     3,707       —         381  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     —         (46,272     (12,395     —         (58,667
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from financing activities

          

Payment of long-term debt, capital leases and other long-term obligations

     (10,440     (632     (196     —         (11,268

Distributions to non-controlling interests

     —         (2,670     (2,238     —         (4,908

Cash paid for the repurchase of non-controlling interests

     —         (169     —         —         (169

Change in intercompany balances with affiliates, net

     73,887       69,439       (120,927     (22,399     —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     63,447       65,968       (123,361     (22,399     (16,345
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Change in cash and cash equivalents

     —         (27,684     2,915       —         (24,769

Cash and cash equivalents at beginning of period

     —         258,811       86,874       —         345,685  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ —       $ 231,127     $ 89,789     $ —       $ 320,916  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

34


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended March 31, 2016 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Cash flows from operating activities

          

Net earnings (loss)

   $ (45,556   $ (43,891   $ 66,966     $ 4,914     $ (17,567

Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:

          

Depreciation and amortization

     —         19,348       33,902       —         53,250  

Amortization of loan costs

     4,012       —         —         —         4,012  

Amortization of deferred gain on sale-leaseback transaction

     (1,248     —         —         —         (1,248

Change in physician minimum revenue guarantees

     —         50       2,000       —         2,050  

Stock-based compensation

     3,344       —         —         —         3,344  

Deferred income taxes

     (8,512     —         —         —         (8,512

Gain on disposal of assets, net

     —         (358     (367     —         (725

Loss (earnings) from discontinued operations, net

     (2,096     5,982       —         —         3,886  

Equity in earnings of affiliates

     (17,672     —         —         17,672       —    

Changes in operating assets and liabilities, net of the effect of acquisitions and dispositions:

          

Accounts receivable, net

     —         (6,899     (17,785     —         (24,684

Inventories, prepaid expenses and other current assets

     —         3,012       27,079       —         30,091  

Accounts payable, other accrued expenses and other accrued liabilities

     (1,151     1,237       34,069       —         34,155  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities — continuing operations

     (68,879     (21,519     145,864       22,586       78,052  

Net cash provided by operating activities — discontinued operations

     —         637       —         —         637  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     (68,879     (20,882     145,864       22,586       78,689  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from investing activities

          

Purchases of property and equipment

     —         (40,214     (21,836     —         (62,050

Cash paid for acquisitions, net

     —         (5,869     (2,311     —         (8,180

Proceeds from sale of assets

     —         121       45       —         166  

Change in other assets, net

     —         (1,434     1,833       —         399  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     —         (47,396     (22,269     —         (69,665
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from financing activities

          

Payment of long-term debt, capital leases and other long-term obligations

     (7,232     (364     (692     —         (8,288

Payment of debt financing costs

     (5,179     —         —         —         (5,179

Distributions to non-controlling interests

     —         —         (5,563     —         (5,563

Cash paid for the repurchase of non-controlling interests

     —         —         (960     —         (960

Change in intercompany balances with affiliates, net

     81,290       13,642       (72,346     (22,586     —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     68,879       13,278       (79,561     (22,586     (19,990
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Change in cash and cash equivalents

     —         (55,000     44,034       —         (10,966

Cash and cash equivalents at beginning of period

  

 

—  

 

    340,052       38,461       —         378,513  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ —       $ 285,052     $ 82,495     $ —       $ 367,547  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

35


Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements, the notes to our unaudited condensed consolidated financial statements and the other financial information appearing elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Data for the quarters and six months ended March 31, 2017 and 2016, have been derived from our unaudited condensed consolidated financial statements. In this Report, unless otherwise stated or indicated by context, references to the “Company,” “IASIS,” “we,” “our” or “us” refer to IASIS Healthcare LLC and its affiliates. Unless the context otherwise implies, the term “affiliates” means direct and indirect subsidiaries of IASIS Healthcare LLC and partnerships and joint ventures in which such subsidiaries are partners. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of IASIS and the term “employees” refers to employees of affiliates of IASIS. References herein to “IAS” are to IASIS Healthcare Corporation, our parent company.

FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Report contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which involve risks and uncertainties. Forward-looking statements include all statements that do not relate solely to historical or current facts, and you can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” “projects,” “continue,” “initiative,” or “anticipates” or similar expressions that concern our prospects, objectives, strategies, plans or intentions. These forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those expected. While we believe our assumptions are reasonable, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. These factors include, but are not limited to:

 

    the effects related to implementation of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Health Reform Law”), the potential repeal or significant modifications of the Health Reform Law, its implementation and/or its interpretation which may result from following the 2016 federal elections, the possible enactment of additional federal or state healthcare reforms and the outcome of court challenges to such laws;

 

    potential additional impacts of the 2016 federal elections and changes to federal, state, or local laws and regulations affecting the healthcare industry;

 

    our Health Choice managed care business’ ability to effectively manage costs of care, maintain its governmental contracts and achieve its service line expansion strategies;

 

    the effects of a shift in volume or payor mix from commercial managed care payors to self-pay and Medicaid;

 

    increases in the amount, and risk of collectability, of uninsured accounts and deductibles and copayment amounts for insured accounts;

 

    a reduction in or withholding of government-sponsored supplemental payments to our hospitals;

 

    the effects of any inability to retain and negotiate reasonable contracts with managed care plans as a result of consolidation among managed care organizations or otherwise;

 

    if insured patients switch from traditional commercial insurance plans to health insurance exchange (“Exchange”) plans;

 

    industry trends towards value-based purchasing and narrow networks and related competitive challenges to our hospitals;

 

    possible changes in the Medicare, Medicaid and other state programs, including Medicaid supplemental reimbursement programs or waiver programs, that may impact reimbursement to healthcare providers and insurers;

 

    controls imposed by Medicare and third-party payors to reduce admissions and length of stay that negatively impact healthcare provider reimbursement;

 

    competition to attract and retain quality physicians, nurses, technicians and other personnel;

 

    the generally competitive nature of the healthcare industry;

 

    the possibility of health pandemics and the related impacts on our operations and financial results;

 

36


Table of Contents
    a failure of our information systems or breach of our cybersecurity protections;

 

    the costs and operational challenges associated with information technology and medical equipment upgrades;

 

    challenges associated with the implementation of electronic health records (“EHRs”) and coding systems;

 

    compliance with extensive healthcare industry laws, regulations and investigations, including those with respect to patient privacy and physician-owned hospitals;

 

    reliance upon services provided by third-party vendors;

 

    the effects of local or national economic downturns on our business lines;

 

    risks associated with our acquisition and development strategy, including liabilities assumed in acquisitions of facilities and physician practices and our need to effectively integrate acquired companies into our existing operations;

 

    increased lease rates and amended lease terms at certain of our facilities in connection with sale-leaseback transactions;

 

    risks associated with environmental, health and safety laws;

 

    risks associated with labor laws;

 

    potential adverse accounting impacts associated with goodwill carrying value;

 

    our dependence upon the services of key executive management personnel;

 

    our ability to maintain adequate internal controls over our financial and management systems;

 

    risks related to our indebtedness and capital structure; and

 

    other risk factors described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016, filed with the SEC on December 21, 2016 (our “2016 Form 10-K”), and in our other public filings with the SEC.

Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this Report speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.

EXECUTIVE OVERVIEW

We are a healthcare services company delivering high-quality, cost-effective healthcare through a broad and differentiated set of capabilities and assets that includes acute care hospitals with related patient access points, and a diversified and growing managed care risk platform (“risk platform”). Our business model is centered on deploying our acute care expertise and risk platform, either separately or on an integrated basis to manage population health, integrate the delivery and payment of healthcare services and ultimately expand our total market opportunities within our existing and new geographic markets. Our business consists of two operating segments: (i) our acute care operations, which, as of March 31, 2017, included 17 acute care hospitals, one behavioral hospital and multiple other access points, including 141 physician clinics, multiple outpatient surgical units, imaging centers, and investments in urgent care centers and on-site employer-based clinics, and (ii) our managed care operations, comprised of our diversified and growing risk platform, Health Choice, which operates managed Medicaid and Medicare health plans, and a management services organization (“MSO”) that provides management and administrative services to third-party insurers, as well as accountable care networks in conjunction with our acute care facilities.

Acute Care Operations

As of March 31, 2017, we owned or leased 17 acute care hospital facilities and one behavioral health hospital facility with a total of 3,600 licensed beds, several outpatient service facilities and 141 physician clinics.

We operate our hospitals with a strong community focus by offering and developing healthcare services targeted to the needs of the markets we serve, promoting strong relationships with physicians and working with local managed care plans to develop quality and outcome driven, cost-efficient and innovative reimbursement models. Our major acute care geographic markets include Salt Lake City, Utah; Phoenix, Arizona; six cities in Texas, including Houston, San Antonio and Odessa; and West Monroe, Louisiana.

 

37


Table of Contents

Since our Company was founded in 1998, we believe we have developed a reputation for operating hospitals that deliver high quality care in our markets at rates that are often more affordable than many other hospitals in our markets with larger local market share than us. Our corporate and divisional infrastructure allows us to leverage savings in information technology services, revenue cycle, hospital supplies, and labor force costs.

Managed Care Operations

Health Choice, headquartered in Phoenix, Arizona, began providing managed Medicaid services under contract with the Arizona Health Care Cost Containment System (“AHCCCS”) in 1990, making it one of the nation’s first Medicaid managed care plans. Under our ownership beginning in 1999, Health Choice has evolved into a managed care organization and insurer which, while it has grown its core managed Medicaid business, has expanded to serve certain Medicare Advantage members and is utilizing its population health management expertise to offer MSO-related services to other payors. In collaboration with our hospitals and affiliated physicians in certain of our markets, Health Choice also manages accountable care provider networks.

Health Choice provides the Company with the ability to engage in innovative value-based purchasing initiatives and opportunities. Its leadership team has considerable experience in population health management, physician relations and network development. We believe Health Choice also deploys state of the art disease management and claims processing technology. In light of the current healthcare industry trends toward integrated delivery and clinical integration, we are seeking to use Health Choice’s expertise and technology in the management of the accountable care provider networks we offer to other health plans.

As of March 31, 2017, Health Choice’s related entities managed healthcare services for 676,700 covered lives through multiple health plans, accountable care networks, MSO-related services and other managed care solutions. These include 282,300 managed Medicaid lives served primarily through Health Choice’s core health plan business in Arizona, 228,600 plan members associated with Health Choice Integrated Care (“HCIC”), (which includes 62,300 Navajo Nation plan members that also receive health plan services through a state of Arizona Tribal Regional Behavioral Health Authority), 9,700 Medicare Advantage members eligible for both Medicare and Medicaid (“Duals”), 97,600 MSO lives and 85,800 lives attributed to our accountable care networks from multiple payors whose care is managed by our network providers, of which 27,300 lives are members in Health Choice’s managed Medicaid and Exchange plans.

Recent Developments

Health Choice Exits Arizona Marketplace Exchange Business. As of January 1, 2017, Health Choice exited the Arizona marketplace exchange. Our decision to exit the exchange was driven by the instability of the Health Reform marketplace, uncertainty and lack of funding around government premium stabilization programs and the overall nature of the related regulatory environment.

Utah Market Acquisitions. In January of 2017, we acquired the assets of two imaging centers in our Salt Lake market from a leading local radiology group. This followed our acquisition, in October 2016, of Riverwoods Surgery Center in Provo, Utah. These acquisitions continue our expansion in the Salt Lake market, which has included investments in a free-standing emergency department, urgent care centers, on-site care centers and other patient access points.

Term Loan Amendment. On May 4, 2017, we, Holdings, certain of our subsidiaries, the lenders party thereto, JPMorgan Chase Bank, N.A., as the Additional Term B-3 Lender (as defined therein), Wilmington Trust, National Association, as administrative agent, and the other agents named therein entered into an Amendment No. 4 to the Amended and Restated Credit Agreement (“Amendment No. 4”). Pursuant to Amendment No. 4, all of the then-outstanding term loans under the Amended and Restated Credit Agreement were refinanced with term loans (the “Term B-3 Loans”) maturing on February 17, 2021, subject to a springing maturity date of 91 days prior to the maturity date of the Senior Notes if any of the Senior Notes remains outstanding as of such date. The interest rate margins applicable to the Term B-3 Loans are 4.00%, for LIBOR-based loans, and 3.00%, for base rate loans, with a LIBOR floor of 1.25%. Amendment No. 4 also provides for a soft call prepayment premium applicable to certain repricing transactions involving the outstanding Term B-3 Loans. The soft call premium equals 1% of the amount of the Term B-3 Loans that are subject to certain repricing transactions occurring on or prior to May 4, 2018. Upon completion of Amendment No. 4, the outstanding term loan balance was $864.2 million, which reflected a $100.0 million pay down to certain holders.

Revolver Amendment. On May 4, 2017, we, Holdings, the lenders party to the Revolving Credit Agreement as of such date and the Revolver Agent entered into an amendment to the Revolving Credit Agreement (“Revolver Amendment No. 1”). Pursuant to Revolver Amendment No. 1, the Revolving Credit Facility matures in February 2021 (the “Stated Revolver Maturity Date”), provided that, if prior to the Stated Revolver Maturity Date, (x) any loans are outstanding under the Term Loan Facility on the date that is 91 days prior to the maturity date of at least $100 million of loans under the Term Loan Facility (such date, the “Springing Term Maturity Date”) or (y) any notes are outstanding under the Indenture on the date that is 91 days prior to the maturity date under the Indenture (such date, the “Springing Notes Maturity Date”), then the maturity date will automatically become the earlier of the Springing Term Maturity Date or the Springing Notes Maturity Date.

 

38


Table of Contents

Revenue and Volume Trends

Total revenue for the quarter ended March 31, 2017, increased 2.6% to $843.0 million, compared to $821.3 million in the same prior year quarter. Total revenue for the six months ended March 31, 2017, increased 3.6% to $1.68 billion, compared to $1.62 billion in the same prior year period. Total revenue is comprised of acute care revenue, which is recorded net of the provision for bad debts, and premium, service and other revenue. Acute care revenue contributed $4.9 million to the increase in total revenue for the quarter ended March 31, 2017, compared to the same prior year quarter, while premium, service and other revenue of our risk platform contributed $16.8 million to the increase in total revenue compared to the same prior year quarter. Acute care revenue contributed $14.5 million to the increase in total revenue for the six months ended March 31, 2017, compared to the same prior year period, while premium, service and other revenue of our risk platform contributed $44.2 million to the increase in total revenue compared to the same prior year period.

Acute Care Revenue

Acute care revenue is comprised of net patient revenue and other revenue. A large percentage of our hospitals’ net patient revenue consists of fixed payment, discounted sources, including Medicare, Medicaid and managed care organizations. Reimbursement for Medicare and Medicaid services are often fixed regardless of the cost incurred or the level of services provided. Similarly, a greater percentage of the managed care companies we contract with reimburse providers on a fixed payment basis regardless of the costs incurred or the level of services provided. Net patient revenue is reported net of discounts and contractual adjustments. The contractual adjustments principally result from differences between the hospitals’ established charges and payment rates under Medicare, Medicaid and various managed care plans. Additionally, discounts and contractual adjustments result from our uninsured discount and charity care programs. Acute care revenue is reported net of the provision for bad debts. Other revenue includes medical office building rental income and other miscellaneous revenue.

For the quarter ended March 31, 2017, admissions and adjusted admissions increased 1.0%, both compared to the same prior year quarter. For the six months ended March 31, 2017, admissions increased 0.7% and adjusted admissions increased 0.3%, both compared to the same prior year period.

For the quarter and six months ended March 31, 2017, total surgeries increased 6.7% and 4.8%, respectively, compared to the same prior year periods.

The following table provides the sources of our hospitals’ gross patient revenue by payor before discounts, contractual adjustments and the provision for bad debt:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2017     2016     2017     2016  

Medicare

     25.7     25.3     25.4     26.4

Managed Medicare

     18.3       15.3       17.4       15.6  

Medicaid and managed Medicaid

     19.8       21.5       20.1       21.2  

Managed care and other

     30.9       32.6       31.9       31.7  

Self-pay

     5.3       5.3       5.2       5.1  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

 

39


Table of Contents

The following table provides the sources of our hospitals’ net patient revenue by payor before the provision for bad debts:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2017     2016     2017     2016  

Medicare

     19.2     18.2     18.7     18.9

Managed Medicare

     12.4       10.3       11.8       10.4  

Medicaid and managed Medicaid

     9.8       11.9       9.8       12.4  

Managed care and other

     42.7       44.3       44.2       43.4  

Self-pay

     15.9       15.3       15.5       14.9  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

See “Item 1 — Business — Sources of Revenue — Acute Care Revenue” and “Item 1 — Business — Government Regulation and Other Factors” included in our 2016 Form 10-K for a description of the types of payments we receive for services provided to patients enrolled in the traditional Medicare plan, managed Medicare plans, Medicaid plans, managed Medicaid plans and managed care plans. In those sections, we also discussed the unique reimbursement features of the traditional Medicare plan, including the annual Medicare regulatory updates published by CMS that impact reimbursement rates for services provided under the plan. The future potential impact to reimbursement for certain of these payors under the Health Reform Law is also discussed in such Annual Report on Form 10-K.

Premium, Service and Other Revenue

Premium, service and other revenue generated by our managed care operations represented 40.2% and 40.4% of our total revenue for the quarter and six months ended March 31, 2017, respectively, compared to 39.2% and 39.1% in the same prior year periods. The increase in the percentage of revenue derived from our managed care operations was due primarily to a 3.1% rate increase at our Arizona Medicaid program, as well as a 5.2% increase in total lives served, excluding our Arizona marketplace exchange business, which we exited as of January 1, 2017.

Health Choice contracts with state Medicaid programs in Arizona and Utah to provide specified health services to qualified Medicaid enrollees through contracted healthcare providers. Most of its premium revenue is derived through its contracts with AHCCCS, the state agency that administers Arizona’s Medicaid program. These contracts require Health Choice to arrange for healthcare services for enrolled Medicaid patients in exchange for fixed monthly premiums, based upon negotiated per capita member rates, and supplemental payments from AHCCCS. Premium revenue includes adjustments to revenue related to the program settlement process for the Arizona managed Medicaid plan under the related state contract. This program settlement process reconciles estimated amounts due to or from the state based on contractually mandated limits on profits and losses. Although estimates of future program settlement amounts are recorded in current periods, the program settlement process typically occurs 18 months post-plan year, when actual (rather than projected) claims and member eligibility data become available and a net settlement amount is determined either due to or from the state. Adjustments to the estimates of future program settlement amounts are recorded as a component of premium revenue.

Health Choice also contracts with CMS to provide coverage as a Medicare Advantage Prescription Drug (“MAPD”) Special Needs Plan (“SNPs”). This contract allows Health Choice to offer Medicare and Part D drug benefit coverage to new and existing dual-eligible members (i.e., those that are eligible for Medicare and Medicaid). In accordance with CMS regulations, SNPs are now expected to meet additional requirements, including requirements relating to model of care, cost-sharing, disclosure of information and reporting of quality measures.

 

40


Table of Contents

Industry Trends and Other Items Impacting Our Company

The following section discusses updates to trends discussed in our 2016 Form 10-K that we believe are significant factors in our current and/or future operating results and cash flows. Certain of these trends apply to the entire acute care hospital industry, while others may apply to us more specifically. These trends could be short-term in nature or could require long-term attention and resources. While these trends may involve certain factors that are outside of our control, the extent to which these trends affect our hospitals and health plan operations and our ability to manage the impact of these trends play vital roles in our current and future success. In many cases, we are unable to predict what impact, if any, these trends will have on us.

Healthcare Reform

In recent years, Congress and certain state governments have passed a large number of laws and regulations intended to result in major changes within the healthcare system. The Health Reform Law, the most prominent of these efforts, changed how healthcare services are covered, delivered and reimbursed through expanded health insurance coverage, reduced growth in Medicare program spending and the establishment of programs that tie reimbursement to care quality and value. However, there is substantial uncertainty regarding the ongoing effects of the Health Reform Law because of the results of the 2016 federal elections, which will likely result in the repeal of, or significant changes to, the Health Reform Law, its implementation or its interpretation. For example, President Donald Trump has signed an executive order that directs agencies to minimize “economic and regulatory burdens” of the Health Reform Law, although it is unclear how this will be implemented. It is difficult to predict when or how the Health Reform Law may be changed, what alternative provisions, if any, will be enacted, the timing of the implementation of any alternative provisions and the impact of alternative provision on providers and other healthcare industry participants. Since the implementation of the Health Reform Law began, as a result of significant pay-for items, including reductions in Medicaid disproportionate share payments, Medicare reimbursement rate reductions, and provider tax assessments in the state of Arizona, we have not seen significant benefit to our earnings. However, while we are unable to predict the full impact of any potential modification or repeal of the Health Reform Law or the implementation thereof on our acute care operations business and/or our managed care operation business, if the Health Reform Law is repealed or significantly modified, such repeal or modification could have a materially adverse impact on our business strategies, prospects, operation results or financial condition.

State Medicaid Budgets

In recent years, the states in which we operate have experienced budget constraints as a result of increased costs and lower than expected tax collections. Health and human services programs, including Medicaid and similar programs, represent a significant portion of state budgets. The states in which we operate responded to these budget concerns by decreasing funding for Medicaid and other healthcare programs or by making structural changes that resulted in a reduction in hospital reimbursement, as well as by imposing more restrictive Medicaid eligibility requirements. In addition, many states have received waivers from CMS in order to implement or expand managed Medicaid programs.

Texas

The Texas legislature and the Texas Health and Human Services Commission (“THHSC”) recommended expanding Medicaid managed care enrollment in the state, and in December 2011, CMS approved a five-year Medicaid waiver, since extended through March 31, 2017, that: (1) allows Texas to expand its Medicaid managed care program while preserving hospital funding; (2) provides incentive payments for improvements in healthcare delivery; and (3) directs more funding to hospitals that serve large numbers of uninsured patients. All of our acute care hospitals in Texas currently receive supplemental Medicaid reimbursement, including reimbursement from programs for participating private hospitals that enter into indigent care affiliation agreements with public hospitals or county governments in the state of Texas. Under the CMS-approved programs, affiliated hospitals, including our Texas hospitals, have expanded the community healthcare safety net by providing indigent healthcare services. Revenue recognized under these Texas private supplemental Medicaid reimbursement programs, including amounts recognized under the Texas Medicaid Disproportionate Share Hospital program (“Texas Medicaid DSH”) for the quarters and six months ended March 31, 2017 and 2016, respectively, was $21.2 million and $47.3 million, respectively, compared to $30.0 million and $58.5 million in the same prior year periods. Under the Medicaid waiver, funds are distributed to participating hospitals based upon both the costs associated with providing care to individuals without third party coverage and the investment made to support coordinating care and quality improvements that transform the local communities’ care delivery systems. The responsibility to coordinate and develop plans that address the concerns of the local delivery care systems, including improved access, quality, cost effectiveness and coordination is controlled primarily by public hospitals or local government entities that serve the surrounding geographic areas. Complexities of the underlying methodologies in determining the funding for the state’s Medicaid supplemental reimbursement programs, along with a lack of sufficient resources at the THHSC to administer the programs, have historically resulted in a delay in related reimbursements. As of March 31, 2017 and September 30, 2016, we had $23.9 million and $29.4 million, respectively, in receivables due to our Texas hospitals in connection with these supplemental reimbursement programs, which includes $0.2 million and $3.6 million, respectively, of amounts due under Texas Medicaid DSH.

 

41


Table of Contents

Arizona

Effective January 1, 2014, Arizona expanded its Medicaid program under the Health Reform Law, which includes increased eligibility for adults, children and pregnant women, and the restoration of eligibility to childless adults that had previously been eliminated. As a result of the Medicaid expansion and of the Plan’s increase in total coverage area under its most recent AHCCCS contract, enrollment under Health Choice’s Medicaid product line increased 7.0% for the quarter ended March 31, 2017, compared to the same prior year quarter. In addition, in connection with the expanded Medicaid coverage, the state implemented a provider assessment to fund a portion of the expanded eligibility related to the childless adult population. During the quarter and six months ended March 31, 2017, we incurred $2.2 million and $4.5 million, respectively, in provider fee assessments compared to $2.1 million and $4.3 million in the same prior year periods.

Further, while the Arizona legislature approved an expansion of Medicaid in 2013 which became effective on January 1, 2014, a lawsuit filed by several state lawmakers has challenged the legality of a provider fee assessed to all providers and used to help pay for Arizona’s Medicaid expansion. On August 26, 2015, the Arizona State Superior Court upheld the legality of the provider fee, thus preserving the existing funding for Medicaid expansion in Arizona. The plaintiffs are appealing this decision. A successful appeal, invalidating the provider fee used to help fund Arizona’s Medicaid expansion, may result in the loss of certain funding for the state’s Medicaid program, which could potentially result in changes that restrict eligibility and increase the number of uninsured individuals, therefore, adversely affecting our operations in Arizona.

Uncompensated Care

Uncompensated care represents discounts provided to the uninsured, bad debts and charity care, associated with the acute care services we deliver to the communities we serve. During the quarter and six months ended March 31, 2017, our uncompensated care as a percentage of acute care revenue was 20.5% and 21.0%, respectively, compared to 20.8% and 20.5% in the same prior year periods. During the quarter ended March 31, 2017, our self-pay admissions represented 6.2% of our total admissions, compared to 6.1% in the same prior year quarter. During the six months ended March 31, 2017, our self-pay admissions represented 6.1% of our total admissions, compared to 6.2% in the same prior year period.

If we were to experience continued growth in uninsured and under-insured volume and revenue, our uncompensated care may continue to increase and our results of operations would continue to be adversely affected.

The percentages of our insured and uninsured net hospital receivables are summarized as follows:

 

     March 31,
2017
    September 30,
2016
 

Insured receivables

     82.7     81.2

Uninsured receivables

     17.3     18.8  
  

 

 

   

 

 

 

Total

     100.0     100.0
  

 

 

   

 

 

 

The percentages of hospital net receivables in summarized aging categories are as follows:

 

     March 31,
2017
    September 30,
2016
 

0 to 90 days

     66.0     63.3

91 to 180 days

     16.8     19.0  

Over 180 days

     17.2     17.7  
  

 

 

   

 

 

 

Total

     100.0     100.0
  

 

 

   

 

 

 

 

42


Table of Contents

Regulatory Matter

On January 14, 2016, CMS entered into a Systems Improvement Agreement (“SIA”) with St. Joseph Medical Center (“SJMC”) located in Houston, Texas. The SIA acted to stay the scheduled termination of SJMC’s Medicare Provider Agreement, which resulted from the hospital’s alleged failure to comply with certain Medicare program conditions of participation. As required by the terms of the SIA, the Company retained an independent consultant to assist it in developing and implementing a corrective action plan. The original term of the SIA was eighteen months. In April 2017, CMS and SJMC amended the SIA to extend it by three-and-a-half months. The SIA is now scheduled to expire sixty days after CMS provides SJMC with written findings following a full certification survey, which survey may occur sometime between July 1, 2017 and October 31, 2017.

Critical Accounting Policies and Estimates

A summary of significant accounting policies is disclosed in Note 2 to the consolidated financial statements included in our 2016 Form 10-K. Our critical accounting policies are further described under the caption “Critical Accounting Policies and Estimates” in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2016 Form 10-K. There have been no changes in the nature of our critical accounting policies or the application of those policies since September 30, 2016.

 

43


Table of Contents

SELECTED OPERATING DATA

The following table sets forth certain unaudited operating data from continuing operations for each of the periods presented.

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2017     2016     2017     2016  

Acute care operations (1)

        

Number of hospital facilities at end of period

     18       18       18       18  

Licensed beds at end of period

     3,600       3,600       3,600       3,600  

Average length of stay (days) (2)

     5.0       5.0       5.0       4.9  

Occupancy rates (average beds in service)

     49.3     49.2     48.3     47.8

Admissions (3)

     26,206       25,948       51,751       51,408  

Adjusted admissions (4)

     49,075       48,606       97,560       97,304  

Patient days (5)

     129,753       130,108       257,071       253,996  

Adjusted patient days (4)

     242,982       243,722       484,623       480,760  

Surgeries

     17,511       16,413       36,171       34,524  

Emergency room visits

     109,969       111,012       213,916       216,359  

Net patient revenue per adjusted admission (6)

   $ 10,185     $ 10,186     $ 10,201     $ 10,076  

Outpatient revenue as a % of gross patient revenue

     46.6     46.6     47.0     47.2

Managed care operations

        

Health plan lives (7)

     520,600       512,600       520,600       512,600  

MSO lives (8)

     97,600       96,600       97,600       96,600  

Accountable care network lives (9)

     58,500       47,000       58,500       47,000  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total lives

     676,700       656,200       676,700       656,200  

Medical loss ratio (10)

     84.0     87.2     84.6     88.4

 

(1) Includes St. Luke’s Behavioral Hospital in Phoenix, Arizona.
(2) Represents the average number of days that a patient stayed in our hospitals.
(3) Represents the total number of patients admitted to our hospitals that qualify for inpatient status. Management and investors use this number as a general measure of inpatient volume.
(4) Adjusted admissions and adjusted patient days are general measures of combined inpatient and outpatient volume. We compute adjusted admissions (or adjusted patient days) by multiplying admissions/patient days by gross patient revenue and then dividing that number by gross inpatient revenue.
(5) Represents the number of days our beds were occupied by inpatients over the period.
(6) Includes the impact of the provision for bad debts as a component of revenue.
(7) Represents total lives enrolled across all health plan product lines.
(8) Represents lives served by Health Choice’s MSO that provides management and administrative services to a large national insurer’s Medicaid plan members in the Tampa and “panhandle” regions of Florida.
(9) Represents attributed health plan member lives from other third-party payors for which Health Choice Preferred accountable care networks manage medical care and participating providers and Health Choice share associated financial risks. This excludes 27,300 and 51,300 attributed Health Choice plan member lives as of March 31, 2017 and 2016, respectively.
(10) Represents medical claims expense as a percentage of premium revenue, including claims paid to our hospitals.

 

44


Table of Contents

RESULTS OF OPERATIONS SUMMARY

Consolidated

The following table sets forth, for the periods presented, the results of our consolidated operations expressed in dollar terms and as a percentage of total revenue. Such information has been derived from our unaudited condensed consolidated statements of operations.

 

     Quarter Ended     Quarter Ended     Six Months Ended     Six Months Ended  
     March 31, 2017     March 31, 2016     March 31, 2017     March 31, 2016  
($ in thousands):    Amount     %     Amount     %     Amount     %     Amount     %  

Revenue

                

Acute care revenue before provision for bad debts

   $ 600,080       $ 598,194       $ 1,202,257       $ 1,179,595    

Less: Provision for bad debts

     (95,825       (98,881       (198,813       (190,696  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     504,255       59.8     499,313       60.8     1,003,444       59.6     988,899       60.9

Premium, service and other revenue

     338,791       40.2     321,974       39.2     679,483       40.4     635,236       39.1
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     843,046       100.0     821,287       100.0     1,682,927       100.0     1,624,135       100.0

Costs and expenses

                

Salaries and benefits

     256,018       30.4     252,269       30.7     511,081       30.4     497,127       30.6

Supplies

     86,850       10.3     84,113       10.2     176,379       10.5     168,964       10.4

Medical claims

     275,335       32.7     268,030       32.6     551,389       32.8     534,737       32.9

Rentals and leases

     22,234       2.6     21,968       2.7     44,036       2.6     43,300       2.7

Other operating expenses

     141,835       16.8     148,137       18.1     279,340       16.6     277,887       17.1

Medicare and Medicaid EHR incentives

     (34     (0.0 %)      (48     (0.0 %)      (805     (0.0 %)      (490     (0.0 %) 

Interest expense, net

     31,915       3.8     34,033       4.1     61,660       3.7     66,643       4.1

Depreciation and amortization

     26,100       3.1     27,057       3.3     52,497       3.0     53,250       3.2

Management fees

     1,250       0.1     1,250       0.2     2,500       0.1     2,500       0.2
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total and expenses

     841,503       99.8     836,809       101.9     1,678,077       99.7     1,643,918       101.2

Earnings (loss) from continuing operations

                

before gain (loss) on disposal of assets and income taxes

     1,543       0.2     (15,522     (1.9 %)      4,850       0.3     (19,783     (1.2 %) 

Gain on disposal of assets, net

     628       0.1     237       0.0     933       0.0     725       0.0
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     2,171       0.3     (15,285     (1.9 %)      5,783       0.3     (19,058     (1.2 %) 

Income tax expense (benefit)

     897       0.1     (4,885     (0.6 %)      2,272       0.1     (5,377     (0.3 %) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     1,274       0.2     (10,400     (1.3 %)      3,511       0.2     (13,681     (0.9 %) 

Earnings (loss) from discontinued operations, net of income taxes

     (762     (0.1 %)      167       0.0     (848     (0.0 %)      (3,886     (0.2 %) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     512       0.1     (10,233     (1.3 %)      2,663       0.2     (17,567     (1.1 %) 

Net earnings attributable to non-controlling interests

     (3,725     (0.3 %)      (2,602     (0.3 %)      (7,626     (0.5 %)      (5,403     (0.3 %) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to IASIS Healthcare LLC

   $ (3,213     (0.4 %)    $ (12,835     (1.6 %)    $ (4,963     (0.3 %)    $ (22,970     (1.4 %) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

45


Table of Contents

Acute Care Operations

The following table and discussion sets forth, for the periods presented, the results of our acute care operations expressed in dollar terms and as a percentage of total acute care revenue. Such information has been derived from our unaudited condensed consolidated statements of operations.

 

    Quarter Ended     Quarter Ended     Six Months Ended     Six Months Ended  
    March 31, 2017     March 31, 2016     March 31, 2017     March 31, 2016  
($ in thousands):   Amount     %     Amount     %     Amount     %     Amount     %  

Acute care revenue

               

Acute care revenue before provision for bad debts

  $ 600,080       $ 598,194       $ 1,202,257       $ 1,179,595    

Less: Provision for bad debts

    (95,825       (98,881       (198,813       (190,696  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

    504,255       99.0     499,313       99.1     1,003,444       99.0     988,899       99.2

Revenue between segments (1)

    4,976       1.0     4,499       0.9     10,089       1.0     8,458       0.8
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total acute care revenue

    509,231       100.0     503,812       100.0     1,013,533       100.0     997,357       100.0

Costs and expenses